Results from the phase 2 RESONATE™-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

被引：0

作者：

Stilgenbauer, S. ^{[1
]}

Jones, J. A. ^{[2
]}

Coutre, S. E. ^{[3
]}

Mato, A. R. ^{[4
]}

Hillmen, P. ^{[5
]}

Tam, C. ^{[6
]}

Osterborg, A. ^{[7
]}

Siddiqi, T. ^{[8
]}

Thirman, M. J. ^{[9
]}

Furman, R. R. ^{[10
]}

Ilhan, O. ^{[11
]}

Keating, M. ^{[12
]}

Call, T. G. ^{[13
]}

Brown, J. R. ^{[14
]}

Stevens-Brogan, M. ^{[15
]}

Li, Y. ^{[15
]}

Clow, F. ^{[15
]}

James, D. F. ^{[15
]}

Chu, A. D. ^{[15
]}

Hallek, M. ^{[16
,17
]}

O'Brien, S. ^{[12
]}

机构：

[1] Univ Ulm, D-89069 Ulm, Germany

[2] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

[3] Stanford Univ, Sch Med, Div Hematol, Stanford Canc Ctr, Stanford, CA 94305 USA

[4] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[5] Leeds Teaching Hosp, St James Inst Onco, Leeds, W Yorkshire, England

[6] Peter MacCallum Canc Ctr, East Melbourne, Australia

[7] Karolinska Univ Hosp Solna, Dept Hematol, Solna, Sweden

[8] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[9] Univ Chicago Med, Hematol Oncol Sect, Chicago, IL USA

[10] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA

[11] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[13] Mayo Clin, Div Hematol, Rochester, MN USA

[14] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA

[15] Pharmacyclics Inc, Sunnyvale, CA USA

[16] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[17] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V291

引用

页码：92 / 92

页数：1

共 50 条

[31] Results of a phase I trial of the proteasome inhibitor carfilzomib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).
Woyach, Jennifer Ann
Flynn, Joseph M.
Jones, Jeffrey Alan
Andritsos, Leslie A.
Lucas, Margaret
Chase, Weihong
Yang, Ying
Lucas, David M.
Sass, Ellen
Waymer, Sharon
Ling, Yonghua
Jiang, Yao
Phelps, Mitch A.
Byrd, John C.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[32] Outcomes of first-line treatment for chronic lymphocytic leukemia (CLL) with 17p deletion (del17p)
Strati, Paolo
Keating, Michael J.
O'Brien, Susan Mary
Ferrajoli, Alessandra
Burger, Jan Andreas
Faderl, Stefan
Jain, Nitin
Wierda, William G.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[33] Zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final results and correlative analysis of lymphocytosis
Xu, Wei
Yang, Shenmiao
Zhou, Keshu
Pan, Ling
Li, Zengjun
Gao, Sujun
Zhou, Daobin
Hu, Jianda
Feng, Ru
Huang, Haiwen
Wang, Tingyu
Li, Dengju
Ji, Meng
Guo, Haiyi
Zhao, Xia
Wu, Binghao
Yu, Yiling
Wang, Yu
Huang, Jane
Novotny, William
Li, Jianyong
LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 712 - 716
[34] A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Maddocks, Kami
Hertlein, Erin
Chen, Timothy L.
Wagner, Amy J.
Ling, Yonghua
Flynn, Joseph
Phelps, Mitch
Johnson, Amy J.
Byrd, John C.
Jones, Jeffrey A.
LEUKEMIA & LYMPHOMA, 2016, 57 (09) : 2212 - 2215
[35] A PHASE 2 STUDY OF THE BTK INHIBITOR IBRUTINIB IN GENETIC RISK-STRATIFIED RELAPSED AND REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Maddocks, K.
Flynn, J. M.
Andritsos, L. A.
Awan, F.
Woyach, J. A.
Grever, M. R.
Stefanos, M.
Lynch, J.
Johnson, A. J.
Byrd, J. C.
Jones, J. A.
HAEMATOLOGICA, 2014, 99 : 522 - 522
[36] Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
Marcelo Pitombeira de Lacerda
Nayara Ribeiro Guedes
Patricia Eiko Yamakawa
Andre Domingues Pereira
Ana Rita Brito Medeiros da Fonseca
Maria Lourdes Lopes Ferrari de Chauffaille
Matheus Vescovi Goncalves
Mihoko Yamamoto
Celso Arrais Rodrigues
Annals of Hematology, 2017, 96 : 1577 - 1578
[37] Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)
de Lacerda, Marcelo Pitombeira
Guedes, Nayara Ribeiro
Yamakawa, Patricia Eiko
Pereira, Andre Domingues
Medeiros da Fonseca, Ana Rita Brito
Lopes Ferrari de Chauffaille, Maria Lourdes
Goncalves, Matheus Vescovi
Yamamoto, Mihoko
Rodrigues, Celso Arrais
ANNALS OF HEMATOLOGY, 2017, 96 (09) : 1577 - 1578
[38] Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial
Tam, Constantine S.
Lamanna, Nicole
O'Brien, Susan M.
Qiu, Lugui
Yang, Keri
Barnes, Gisoo
Wu, Ken
Salmi, Tommi
Brown, Jennifer R.
CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (11) : 1497 - 1503
[39] Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Huang, Xiaojun
Qiu, Lugui
Jin, Jie
Zhou, Daobin
Chen, Xiequn
Hou, Ming
Hu, Jianda
Hu, Yu
Ke, Xiaoyan
Li, Junmin
Liang, Yingmin
Liu, Ting
Lv, Yue
Ren, Hanyun
Sun, Aining
Wang, Jianmin
Zhao, Chunting
Salman, Mariya
Sun, Steven
Howes, Angela
Wang, Jingzhao
Wu, Peng
Li, Jianyong
CANCER MEDICINE, 2018, 7 (04): : 1043 - 1055
[40] Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE™ Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report
Montillo, Marco
O'Brien, Susan
Tedeschi, Alessandra
Hillmen, Peter
Dearden, Claire
Gill, Devinder
Brown, Jennifer R.
Barrientos, Jaqueline C.
Mulligan, Stephen
Furman, Richard R.
Cymbalista, Florence
Plascencia, Clara
Chang, Stephen
Hsu, Emily
James, Danelle F.
Byrd, John C.
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →